Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Novel Method to Identify Illicit Designer Drugs Developed

By BOSTON UNIVERSITY MEDICAL CENTER | November 14, 2016

A new technique has been identified that quickly and cheaply recognizes illegal designer drugs that normally evade detection.

The findings, described online in the journal Forensic Science International, will assist law enforcement officials investigating overdose and death investigations involving illicit substances.

New psychoactive substances have been associated with fatalities and severe injuries in a number of cases in the U.S. and have led investigators to rethink traditional drug monitoring protocols. Of particular interest are the variable phenethylamine chemical structures known as NBOMes. Given that compounds such as NBOMes are modified with the goal of avoiding detection by routine techniques, forensic laboratories are faced with the challenge of identifying these compounds quickly and accurately.

Researchers from Boston University School of Medicine (BUSM) used a method known as Direct Sample Analysis Time-of-Flight Mass Spectrometry (TOFMS) to identify NBOMe compounds on blotter paper in as little as 15 seconds.

According to the researchers this technique will help increase the efficiency for forensic laboratories that are faced with growing caseloads and limited resources. An additional benefit is that TOFMS has the unique capacity to use data from previously analyzed drug material that couldn’t be identified to be reevaluated for possible identification.

“Over the past five to 10 years, types of illicit drugs used around the world have been created or repurposed from research chemicals to mimic the effects of traditional drugs of abuse in order to circumvent legal control and detection,” explained corresponding author Sabra Botch-Jones, MS, MA, D-ABFT, forensic toxicologist and instructor in the Biomedical Forensic Sciences program in the department of anatomy and neurobiology at BUSM.

Botch-Jones hopes that the development of this faster and more accurate analytical method will assist the public health sector and law enforcement in conducting risk assessments and implementing control measures for designer drugs.

This research was performed in collaboration with PerkinElmer and the use of their instrumentation.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE